Curated News
By: NewsRamp Editorial Staff
August 25, 2026
Annovis Bio to Host Webinar on Alzheimer's and Parkinson's Progress
TLDR
- Annovis Bio's Phase 3 Alzheimer's trial complete enrollment, top-line data and regulatory submissions expected in 2027, positioning for market advantage.
- Annovis Bio's buntanetap inhibits translation of neurotoxic proteins via RNA-targeting mechanism, with ongoing open-label studies for long-term safety data.
- Annovis Bio aims to halt Alzheimer's and Parkinson's progression, improving cognitive and motor functions for patients, offering hope for better tomorrows.
- Annovis Bio's corporate update webinar on Sept. 2, 2026, includes a live Q&A with CEO Maria Maccecchini, discussing milestones and new Parkinson's dementia program.
Impact - Why it Matters
This news matters because it highlights the potential of buntanetap to become a groundbreaking treatment for Alzheimer's and Parkinson's diseases, conditions that affect millions worldwide and currently lack disease-modifying therapies. The upcoming data readouts and regulatory submissions could significantly alter the treatment landscape, offering hope for patients and families. For investors, the progress of Annovis's clinical trials represents a high-stakes opportunity, as positive results could lead to substantial market impact and a new standard of care in neurodegenerative disease management.
Summary
Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, is set to host a corporate update webinar on September 2, 2026, at 4 p.m. EDT, to discuss its progress and upcoming milestones in developing treatments for Alzheimer's and Parkinson's diseases. The webinar will feature founder, President and CEO Maria Maccecchini, Ph.D., and will include a live Q&A session. Key topics include the fully enrolled pivotal Phase 3 Alzheimer's disease (AD) trial, with top-line data and regulatory submissions expected in 2027, and the launch of an AD open-label study in October 2026 to gather long-term safety data. The company's Parkinson's disease (PD) open-label study is already underway, and discussions are ongoing for a Parkinson's disease dementia program.
Annovis's lead drug candidate, buntanetap, is an investigational oral therapy that targets multiple neurotoxic proteins implicated in neurodegeneration, including amyloid beta, tau, alpha-synuclein, and TDP-43, through a novel RNA-targeting mechanism. By addressing the root causes of these diseases, Annovis aims to halt progression and improve cognitive and motor functions. The company, headquartered in Malvern, Pennsylvania, is dedicated to advancing treatments for neurodegenerative conditions. For more information, visit the company's website and follow on social media. The full press release is available at https://ibn.fm/mls3F.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Annovis Bio to Host Webinar on Alzheimer's and Parkinson's Progress
